osteoprotegerin and Aortic-Aneurysm

osteoprotegerin has been researched along with Aortic-Aneurysm* in 2 studies

Other Studies

2 other study(ies) available for osteoprotegerin and Aortic-Aneurysm

ArticleYear
Expression of Tissue microRNAs in Ascending Aortic Aneurysms and Dissections.
    Angiology, 2023, Volume: 74, Issue:1

    Little is known about the role of serum and tissue mediators in the progression of ascending aortic aneurysms and dissections. We examined how the tissue expression of microRNAs and matrix metalloproteinases (MMPs), as well as the serum levels of osteoprotegerin, adiponectin, and high sensitivity C-reactive protein (hsCRP) are associated with these entities. We enrolled 21 patients with ascending aortic aneurysm, 11 with acute Stanford type A aortic dissection and 18 controls. The serum levels of osteoprotegerin, adiponectin, and hsCRP, as well as the tissue expression of MMPs 2 and 9 and tissue microRNAs 29 and 195 were compared among groups. There was no difference regarding serum osteoprotegerin, adiponectin, and tissue

    Topics: Adiponectin; Aneurysm, Ascending Aorta; Aortic Aneurysm; Aortic Aneurysm, Thoracic; C-Reactive Protein; Humans; Matrix Metalloproteinases; MicroRNAs; Osteoprotegerin

2023
OPG/TRAIL ratio as a predictive biomarker of mortality in patients with type A acute aortic dissection.
    Nature communications, 2021, 06-07, Volume: 12, Issue:1

    Following hospital discharge, patients with type A acute aortic dissection (TA-AAD) may present an increase in mortality risk. However, little is known about specific biomarkers associated with post-discharge survival, and there is a paucity of prognostic markers associated with TA-AAD. Here, we identify nine candidate proteins specific for patietns with TA-AAD in a cross-sectional dataset by unbiased protein screening and in-depth bioinformatic analyses. In addition, we explore their association with short-term and long-term mortality in a derivation cohort of patients with TA-AAD, including an internal (n = 300) and external (n = 236) dataset. An elevated osteoprotegerin (OPG)/tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) ratio was the strongest predictor of overall, 30-day, post-30-day mortality in both datasets and was confirmed to be a strong predictor of mortality in an independent validation cohort (n = 400). Based on OPG/TRAIL ratio-guided risk stratification, patients at high risk (>33) had a higher 1-year mortality (55.6% vs. 4.3%; 68.2% vs. 2.6%) than patients at low risk (<4) in both cohorts. In Conclusion, we show that an elevated OPG/TRAIL ratio is associated with a significant increase in short-term and long-term mortality in patients with TA-AAD.

    Topics: Adult; Aortic Aneurysm; Aortic Dissection; Biomarkers; Cross-Sectional Studies; Datasets as Topic; Disease-Free Survival; Female; Follow-Up Studies; Hospital Mortality; Humans; Male; Middle Aged; Osteoprotegerin; Patient Discharge; Predictive Value of Tests; Prospective Studies; Risk Assessment; TNF-Related Apoptosis-Inducing Ligand

2021